You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,879,325

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,879,325

Title:	Method for predicting the responsiveness a patient to a treatment with an anti-CD20 antibody
Abstract:	The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.
Inventor(s):	Chiche; Johanna (Nice, FR), Thieblemont; Catherine (Paris, FR), Ricci; Jean-Ehrland (Nice, FR)
Assignee:	ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR)
Application Number:	15/121,864
Patent Claims:	1. A method for treating a patient having non Hodgkin's B cell lymphoma wherein the non Hodgkin's B cell lymphoma is diffuse large B-cell lymphoma, said method comprising the steps of: a) identifying a responder patient having diffuse large B-cell lymphoma that is responsive to treatment with an anti human CD20 antibody by measuring a level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in tumor B-cells obtained from said patient, wherein a high level of GAPDH expression is predictive of a response to said anti-CD20 antibody treatment; and b) treating with said anti-CD20 antibody the responder patient identified. 2. The method according to claim 1, wherein the anti-CD20 antibody is selected from the group consisting of rituximab, ibritumomab, ofatumumab, ocrelizumab, PRO131921,veltuzumab, AME-133v, tositumomab, and GA-101. 3. The method according to claim 1, wherein the anti-CD20 antibody is rituximab.

Details for Patent 9,879,325

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2034-03-03
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	10/26/2009	⤷ Try a Trial	2034-03-03
Novartis Pharmaceuticals Corporation	ARZERRA	ofatumumab	Injection	125326	04/01/2011	⤷ Try a Trial	2034-03-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.